NOT KNOWN FACTUAL STATEMENTS ABOUT PAOPA

There have been no clinically major discrepancies while in the pharmacokinetics of either midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when made use of concomitantly with finerenone. Various doses of 40 mg finerenone once-daily had no clinically pertinent impact on AUC or Cmax in the BCRP and OATP substrate rosuvastatin.Particular